Cue Biopharma (CUE) stock price, revenue, and financials

Cue Biopharma market cap is $479 m, and annual revenue was $3.15 m in FY 2020

$479 M

CUE Mkt cap, 12-Nov-2021

$3.2 M

Cue Biopharma Revenue FY, 2020
Cue Biopharma Net income (FY, 2020)-44.8 M
Cue Biopharma EBIT (FY, 2020)-45 M
Cue Biopharma Cash, 31-Dec-202074.9 M
Cue Biopharma EV411.2 M
Get notified regarding key financial metrics and revenue changes at Cue BiopharmaLearn more
Banner background

Cue Biopharma Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.5m3.2m

R&D expense

1.5m5.7m18.9m28.5m27.5m33.5m

General and administrative expense

425.1k2.0m4.3m11.3m12.7m14.7m

Operating expense total

1.9m7.7m23.2m39.8m40.2m48.2m

EBIT

(1.9m)(7.7m)(23.2m)(38.7m)(36.8m)(45.0m)

EBIT margin, %

(1063%)(1428%)

Interest expense

418.7k463.9k

Interest income

52.035.0376.0k

Pre tax profit

(38.2m)(36.3m)(44.6m)

Income tax expense

825.0k412.5k206.3k

Net Income

(1.9m)(7.7m)(23.2m)(39.0m)(36.7m)(44.8m)

EPS

(0.3)(1.0)(2.2)

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.1m900.0k1.1m

R&D expense

5.8m5.4m10.3m8.4m6.9m9.9m8.1m

General and administrative expense

1.7m2.2m2.9m3.4m3.4m4.0m3.9m

Operating expense total

7.5m7.6m13.2m11.8m10.3m13.9m12.0m

EBIT

(7.5m)(7.5m)(12.8m)(11.4m)(9.2m)(13.0m)(10.9m)

EBIT margin, %

(875%)(1444%)(1018%)

Interest expense

1.0k96.0k203.0k134.0k

Interest income

170.0k102.0k114.0k

Pre tax profit

(9.1m)(10.8m)

Income tax expense

413.0k

Net Income

(7.5m)(7.3m)(12.6m)(11.3m)(9.5m)(7.0m)(12.8m)(10.8m)

Cue Biopharma Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.4m14.9m63.5m10.5m44.3m74.9m

Accounts Receivable

754.9k1.4m

Prepaid Expenses

51.4k162.4k403.4k1.3m860.1k1.2m

Current Assets

6.5m15.1m65.1m40.6m61.0m87.5m

PP&E

709.5k1.0m1.7m2.8m1.8m2.1m

Total Assets

7.3m16.3m67.0m45.4m71.6m99.5m

Accounts Payable

177.8k550.0k1.3m2.0m882.7k2.1m

Short-term debt

4.4m4.8m

Current Liabilities

342.2k1.1m5.3m6.2m11.7m16.3m

Long-term debt

1.3m2.4m

Non-Current Liabilities

34.1k36.4k

Total Debt

5.8m7.1m

Total Liabilities

376.3k1.1m5.3m11.4m17.0m20.6m

Common Stock

7.4k10.6k19.5k20.7k26.6k30.4k

Additional Paid-in Capital

8.9m24.8m94.4m105.8m163.1m232.2m

Retained Earnings

(1.9m)(9.6m)(32.8m)(71.8m)(108.5m)(153.3m)

Total Equity

6.9m15.2m61.6m34.0m54.6m78.9m

Financial Leverage

1.1 x1.1 x1.1 x1.3 x1.3 x1.3 x

Cue Biopharma Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.9m)(7.7m)(23.2m)(39.0m)(36.7m)(44.8m)

Depreciation and Amortization

44.8k202.1k419.6k760.0k810.8k1.1m

Accounts Receivable

(754.9k)(662.6k)

Accounts Payable

177.8k372.1k561.6k376.1k(1.2m)741.3k

Cash From Operating Activities

(1.7m)(6.0m)(12.2m)(26.4m)(30.8m)(32.5m)

Purchases of PP&E

(754.3k)(516.0k)(1.0m)(1.9m)(46.4k)(595.3k)

Cash From Investing Activities

(804.3k)(516.0k)(1.2m)(20.4m)3.4m4.5m

Cash From Financing Activities

8.9m15.0m62.0m4.2m50.8m58.6m

Net Change in Cash

6.4m8.5m48.6m(42.6m)23.4m30.6m

Cue Biopharma Ratios

USDFY, 2015

Financial Leverage

1.1 x